Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Seegene launches new in-silico-based multiplex real-time PCR assays

MDBR Staff Writer Published 04 August 2016

Seegene has expanded its product portfolio with the introduction of new in-silico-based multiplex real-time PCR assays.

SGsilico, which is an automated real-time PCR assay development, can reduce the assay development time from 3-12 months to less than a week.

The customers will be provided with fully configured custom assay kit, comprising of oligonucleotides, optimal enzyme and multiplex real-time PCR condition.

Seegene has digitalized its proprietary real-time PCR technologies and simplified assay with its universal oligo to integrate with in-silico-based development solution.

The company’s DPO, TOCE and MuDT technologies will be used for simultaneous amplification and quantitative detection of multiple targets without disrupting specificity, sensitivity and reproducibility.

In addition, the firm has developed a new SGoligo universal fluorescent-labeled oligo system, which can be applied to different targets regardless of target types.

Seegene founder and CEO Dr Jong-Yoon Chun said: “SGsilico is by far the best solution in regards to its simplicity, time savings, and cost effectiveness in assay development.

“This solution can be used in research areas such as infectious diseases, cancers, and other genetic disorders.

“Seegene’s technology can also be implemented in various non-human diagnosis areas such as food safety, animal, and plant.”

Seegene, which develops multiplex real-time PCR technologies, has subsidiaries in the US, Canada, Italy, and the Middle-East. It also has branch office in Germany and a joint venture in Mexico.